Condition (MeSH)
Mediastinitis
ClinicalTrials.gov lists 21 trials for Mediastinitis or a narrower condition beneath it. Merck Sharp & Dohme LLC has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
21 of the 21 trials are tagged with Mediastinitis itself; the rest are tagged with a narrower condition beneath it.
When did Mediastinitis trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2/3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2019 | 1 |
| 2017 | 2 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 3 |
| 2012 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 21 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Mediastinitis trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2/3 | 1 |
| Phase 4 | 3 |
| Not applicable | 8 |
| Observational | 9 |
How many Mediastinitis trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Active, not recruiting | 1 |
| Completed | 12 |
| Terminated | 1 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Mediastinitis trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 1 |
Which drugs are being tested for Mediastinitis? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Delafloxacin | 1 |
| Alfacalcidol | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Vancomycin (VAN) treatment | 1 |
| V710 | 1 |
| Daptomycin (DAP) treatment | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Mediastinitis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Wound infection staphylococcal | 52 | 1 |
| Multi-organ failure | 49 | 2 |
| Cardiac arrest | 44 | 2 |
| Cardiogenic shock | 41 | 1 |
| Staphylococcal bacteraemia | 37 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Mediastinitis? (59)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A Retrospective Evaluation of the Treatment Effects of Rituximab in Patients with Progressive and Symptomatic Fibrosing Mediastinitis. | Annals of the American Thoracic Society | 2024 | Yes |
| Incidence and predictors of in-stent restenosis following intervention for pulmonary vein stenosis due to fibrosing mediastinitis. | Orphanet journal of rare diseases | 2024 | Yes |
| Prognostic factors for descending necrotizing mediastinitis development in deep space neck infections-a retrospective study. | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | 2022 | Yes |
| Mediastinitis in the intensive care unit patient: a narrative review. | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2020 | Yes |
| Clinical predictors of descending necrotizing mediastinitis after deep neck infections. | The Laryngoscope | 2020 | Yes |
Showing 5 of 59 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.